Fideuram Intesa Sanpaolo Private Banking S.P.A. Grows Stake in Pfizer Inc. $PFE

Fideuram Intesa Sanpaolo Private Banking S.P.A. grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 754.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 657,881 shares of the biopharmaceutical company’s stock after purchasing an additional 580,924 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A.’s holdings in Pfizer were worth $18,473,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in PFE. Norges Bank acquired a new position in Pfizer during the 4th quarter valued at about $1,830,986,000. Morgan Stanley grew its stake in shares of Pfizer by 19.2% during the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after acquiring an additional 14,342,946 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Pfizer by 38.9% during the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after acquiring an additional 13,581,757 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Pfizer by 47.8% during the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after acquiring an additional 8,108,887 shares in the last quarter. Finally, Janus Henderson Group PLC raised its position in shares of Pfizer by 577.5% in the 4th quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock valued at $218,817,000 after purchasing an additional 7,489,189 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $24.29 on Friday. The stock has a 50-day simple moving average of $25.68 and a two-hundred day simple moving average of $26.24. The firm has a market capitalization of $138.45 billion, a P/E ratio of 18.54 and a beta of 0.35. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.1%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is currently 131.30%.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Sunday, June 21st. UBS Group reaffirmed a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Wednesday, May 27th. Cantor Fitzgerald reissued a “neutral” rating on shares of Pfizer in a report on Monday, June 1st. Citigroup upped their target price on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Finally, Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $28.82.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.